Funding agencies: The Goldwurm site acknowledges the funding support of the Italian Telethon Foundation (grant no.: GTB07001) and the “Fondazione Grigioni per il Morbo di Parkinson.” The Maraganore site acknowledges the funding support of the National Institutes of Health (R01 ES10751). The Morrison site acknowledges the funding support of the Medical Research Council UK, Midlands Neuroscience Teaching and Research Fund, and Queen Elizabeth Hospital Birmingham Charity. The Theuns/Van Broeckhoven site acknowledges the funding support of the Interuniversity Attraction Poles program of the Belgian Science Policy Office, the Foundation for Alzheimer Research, the Belgian Parkinson Foundation, the Methusalem Excellence Program of the Flemish Government, the Research Foundation Flanders, the Agency for Innovation by Science and Technology Flanders, and the Special Research Fund of the University of Antwerp, Antwerp, Belgium. The Wszolek site acknowledges the funding support of the National Institutes of Health (P50 NS072187) and the Mayo Clinic Florida Research Committee CR program.
Alpha-synuclein repeat variants and survival in Parkinson's disease
Article first published online: 27 FEB 2014
© 2014 International Parkinson and Movement Disorder Society
Volume 29, Issue 8, pages 1053–1057, July 2014
How to Cite
Chung, S. J., Biernacka, J. M., Armasu, S. M., Anderson, K., Frigerio, R., Aasly, J. O., Annesi, G., Bentivoglio, A. R., Brighina, L., Chartier-Harlin, M.-C., Goldwurm, S., Hadjigeorgiou, G., Jasinska-Myga, B., Jeon, B. S., Kim, Y. J., Krüger, R., Lesage, S., Markopoulou, K., Mellick, G., Morrison, K. E., Puschmann, A., Tan, E.-K., Crosiers, D., Theuns, J., Van Broeckhoven, C., Wirdefeldt, K., Wszolek, Z. K., Elbaz, A., Maraganore, D. M. and on behalf of the Genetic Epidemiology of Parkinson's Disease Consortium (2014), Alpha-synuclein repeat variants and survival in Parkinson's disease. Mov. Disord., 29: 1053–1057. doi: 10.1002/mds.25841
Relevant conflicts of interest/financial disclosures: Demetrius M. Maraganore, MD has licensed an invention to Alnylam Pharmaceuticals, Inc. regarding a method to treat Parkinson's disease. He has received less than $25,000 in royalties. The remaining authors have nothing to declare.
- Issue published online: 17 JUL 2014
- Article first published online: 27 FEB 2014
- Manuscript Accepted: 20 JAN 2014
- Manuscript Revised: 15 JAN 2014
- Manuscript Received: 9 AUG 2013
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.